1 - 25 of 31 results for author:"Badve S." in Literature citations
Results Customize
› Repeat search in UniProtKB (1)
| PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. Johnson E.O., Chang K.H., de Pablo Y., Ghosh S., Mehta R., Badve S., Shah K. J. Cell. Sci. 124:2711-2722(2011) · Mapped (3) |
| FOXA1 is an independent prognostic marker for ER-positive breast cancer. Mehta R.J., Jain R.K., Leung S., Choo J., Nielsen T., Huntsman D., Nakshatri H., Badve S. Breast Cancer Res. Treat. 131:881-890(2012) · Mapped (1) |
| High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Jain R.K., Mehta R.J., Nakshatri H., Idrees M.T., Badve S.S. Histopathology 58:766-772(2011) · Mapped (1) |
| Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Patel J.B., Appaiah H.N., Burnett R.M., Bhat-Nakshatri P., Wang G., Mehta R., Badve S., Thomson M.J., Hammond S., Steeg P. et al. Oncogene 30:1290-1301(2011) · Mapped (2) |
| Podoplanin, a novel marker for seminoma: A comparison study evaluating immunohistochemical expression of podoplanin and OCT3/4. Idrees M., Saxena R., Cheng L., Ulbright T.M., Badve S. Ann Diagn Pathol 14:331-336(2010) · Mapped (3) |
| Pro-inflammatory angiogenesis is mediated by p38 MAP kinase. Rajashekhar G., Kamocka M., Marin A., Suckow M.A., Wolter W.R., Badve S., Sanjeevaiah A.R., Pumiglia K., Rosen E., Clauss M. J. Cell. Physiol. 226:800-808(2011) · Mapped (8) |
| ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. Appaiah H., Bhat-Nakshatri P., Mehta R., Thorat M., Badve S., Nakshatri H. Cancer Biol. Ther. 10:600-614(2010) · Mapped (17) |
| Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Gokmen-Polar Y., Toroni R.A., Hocevar B.A., Badve S., Zhao Q., Shen C., Bruckheimer E., Kinch M.S., Miller K.D. Breast Cancer Res. Treat. 127:375-384(2011) · Mapped (58) |
| Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. Badve S., Collins N.R., Bhat-Nakshatri P., Turbin D., Leung S., Thorat M., Dunn S.E., Geistlinger T.R., Carroll J.S., Brown M. et al. Am. J. Pathol. 176:2139-2149(2010) · Mapped (11) |
| Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Sparano J.A., Goldstein L.J., Childs B.H., Shak S., Brassard D., Badve S., Baehner F.L., Bugarini R., Rowley S., Perez E. et al. Clin. Cancer Res. 15:7693-7700(2009) · Mapped (2) |
| Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Ademuyiwa F.O., Thorat M.A., Jain R.K., Nakshatri H., Badve S. Mod. Pathol. 23:270-275(2010) · Mapped (7) |
| Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Resetkova E., Reis-Filho J.S., Jain R.K., Mehta R., Thorat M.A., Nakshatri H., Badve S. Breast Cancer Res. Treat. 123:97-108(2010) · Mapped (4) |
| The EP1 subtype of prostaglandin E2 receptor: role in keratinocyte differentiation and expression in non-melanoma skin cancer. Konger R.L., Billings S.D., Prall N.C., Katona T.M., Dasilva S.C., Kennedy C.R., Badve S., Perkins S.M., Lacelle P.T. Prostaglandins Leukot. Essent. Fatty Acids 81:279-290(2009) · Mapped (2) |
| FOXA1 in breast cancer. Nakshatri H., Badve S. Expert Rev Mol Med 11:e8-e8(2009) · Mapped (61) |
| COX-2 expression does not correlate with microvessel density in breast cancer. Thorat M.A., Mehrotra S., Morimiya A., Badve S. Pathobiology 76:39-44(2009) · Mapped (5) |
| Amplified in breast cancer 1 expression in breast cancer. Thorat M.A., Turbin D., Morimiya A., Leung S., Zhang Q., Jeng M.H., Huntsman D.G., Nakshatri H., Badve S. Histopathology 53:634-641(2008) · Mapped (8) |
| AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Bhat-Nakshatri P., Wang G., Appaiah H., Luktuke N., Carroll J.S., Geistlinger T.R., Brown M., Badve S., Liu Y., Nakshatri H. Mol. Cell. Biol. 28:7487-7503(2008) · Mapped (63) |
| Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., Flockhart D.A., Hancock B., Davidson N., Gralow J. et al. J. Clin. Oncol. 26:4672-4678(2008) · Mapped (10) |
| Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Hammoud Z., Tan B., Badve S., Bigsby R.M. Endocr. Relat. Cancer 15:475-483(2008) · Mapped (17) |
| Prostanoid receptor EP1 expression in breast cancer. Thorat M.A., Morimiya A., Mehrotra S., Konger R., Badve S.S. Mod. Pathol. 21:15-21(2008) · Mapped (2) |
| Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Prasad N.K., Tandon M., Badve S., Snyder P.W., Nakshatri H. Carcinogenesis 29:25-34(2008) · Mapped (1) |
| FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Badve S., Turbin D., Thorat M.A., Morimiya A., Nielsen T.O., Perou C.M., Dunn S., Huntsman D.G., Nakshatri H. Clin. Cancer Res. 13:4415-4421(2007) · Mapped (1) |
| FOXA1 as a therapeutic target for breast cancer. Nakshatri H., Badve S. Expert Opin. Ther. Targets 11:507-514(2007) · Mapped (1) |
| NuMA influences higher order chromatin organization in human mammary epithelium. Abad P.C., Lewis J., Mian I.S., Knowles D.W., Sturgis J., Badve S., Xie J., Lelievre S.A. Mol. Biol. Cell 18:348-361(2007) · Mapped (12) |
| Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. Mehrotra S., Morimiya A., Agarwal B., Konger R., Badve S. J. Pathol. 208:356-363(2006) · Mapped (3) |